Michael J Allen, Amy Zhang, Samuel D Saibil, Sarah Picardo, Shari Moura, Grainne M O’Kane and Jennifer J Knox
Abstract
PALB2 (Partner and Localizer of Breast Cancer Type 2 (BRCA2)) pathogenic variants increase sensitivity to poly (ADP-ribose) Polymerase Inhibitors (PARPi) in a variety of malignancies, yet no documented objective response to treatment in metastatic pancreatic cancer has been reported. We describe a case of a PALB2-mutated metastatic pancreatic cancer patient who had achieved a partial response to platinum-based chemotherapy, and was then observed to achieve an ongoing partial response with a further 42% reduction in tumor size over 6-months of treatment to date whilst on the PARPi olaparib.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi